Supreme Pharmaceuticals Inc.: South Okanagan MMPR Application Update
June 18 2014 - 9:15AM
Marketwired
Supreme Pharmaceuticals Inc.: South Okanagan MMPR Application
Update
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 18, 2014) -
Supreme Pharmaceuticals Inc. ("Supreme" or the "Company")
(OTCBB:SPRWF)(CSE:SL) is pleased to report that the target company
(or the "Vendor") at Facility 1 has received and replied to the
Department of Health Canada on its Marihuana for Medical Purposes
Regulations Licence (MMPR) application, who required additional
information on:
- External and internal security measures
- Updated site survey and aerial photographs
- Further information on principal and proposed technical
employees
- Details on record keeping and information handling
procedures
The Vendor has engaged external consultants and specialists to
assist in the application process who have been able to respond and
provide the requested documentation in a timely manner. While the
Vendor is confident that their prior experience and expertise in
the industry and the high commercial standards of the production
facility will enable full compliance with Department of Health
requirements for a full commercial MMPR license, there is no
guarantee a MMPR license will be granted.
Last week management of Supreme and its operating subsidiary met
with government officials, including the fire chief, local
politicians, and community stakeholders in the township where its
Southern Ontario green house facility (Facility 2) is located. The
Company does not foresee any concerns in this area as construction
progresses such that it may eventually receive final receipt of the
MMPR license.
Management of Supreme stated: "We are pleased to be making
headway on both projects, being the South Okanagan and Southern
Ontario facilities. The Company is moving forward and will continue
to update shareholders on continued progress."
FORWARD-LOOKING INFORMATION
This news release contains forward-looking statements. The use
of any of the words "anticipate", "continue", "estimate", "expect",
"may", "will", "project", "should", "believe" and similar
expressions are intended to identify forward-looking statements.
Although the Company believes that the expectations and assumptions
on which the forward-looking statements are based are reasonable,
undue reliance should not be placed on the forward-looking
statements because the Company can give no assurance that they will
prove to be correct. This news release includes forward-looking
statements with respect to the acquisition of an MMPR license in
respect to its Southern Okanagan facility, the timing on
competition of the MMPR License conditions for its Southern Ontario
facility and the start of production. Since forward-looking
statements address future events and conditions, by their very
nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this news release. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks including various risk factors
discussed in the Company's disclosure documents which can be found
under the Company's profile on www.sedar.com and such factors as
the Company failing to acquire final MMPR licenses and put the same
into production. This news release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E the Securities Exchange Act of
1934, as amended and such forward-looking statements are made
pursuant to the safe harbour provisions of the Private Securities
Litigation Reform Act of 1995.
Investor Relations430 - 580 Hornby Street, Vancouver BCV6C
3B6Phone: (647) 340-6744Email:
info@supremepharmaceuticals.comWebsite:
www.supremepharmaceuticals.com